BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582-589. [PMID: 17661414 DOI: 10.1002/hep.21768] [Cited by in Crossref: 294] [Cited by in F6Publishing: 282] [Article Influence: 19.6] [Reference Citation Analysis]
Number Citing Articles
1 Chitapanarux T, Tienboon P, Pojchamarnwiputh S, Leelarungrayub D. Open-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients. Journal of Gastroenterology and Hepatology 2009;24:1045-50. [DOI: 10.1111/j.1440-1746.2009.05865.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
2 Wang X, Ren Q, Wu T, Guo Y, Liang Y, Liu S. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice. Mol Med Rep 2014;10:2917-23. [PMID: 25310357 DOI: 10.3892/mmr.2014.2623] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Capitan V, Petit J, Aho S, Lefevre P, Favelier S, Loffroy R, Hillon P, Krausé D, Cercueil J, Guiu B. Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. Eur Radiol 2012;22:2161-8. [DOI: 10.1007/s00330-012-2468-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
4 Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver Int 2019;39:1742-54. [PMID: 31169972 DOI: 10.1111/liv.14167] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
5 Iannelli A, Martini F, Schneck AS, Ghavami B, Baudin G, Anty R, Gugenheim J. Preoperative 4-week supplementation with omega-3 polyunsaturated fatty acids reduces liver volume and facilitates bariatric surgery in morbidly obese patients. Obes Surg 2013;23:1761-5. [PMID: 23686653 DOI: 10.1007/s11695-013-0942-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
6 Clark PJ, Patel K. Noninvasive tools to assess liver disease. Curr Opin Gastroenterol. 2011;27:210-216. [PMID: 21248634 DOI: 10.1097/MOG.0b013e328343e9a3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
7 Lin J, Pan S, Zheng W, Huang Z. Polarization-resolved second-harmonic generation imaging for liver fibrosis assessment without labeling. Appl Phys Lett 2013;103:173701. [DOI: 10.1063/1.4826516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
8 Ruan G, Zhang T, Li L, Zhang X, Shen Y, Tabata Y, Gao J. Hepatic-Targeted Gene Delivery Using Cationic Mannan Vehicle. Mol Pharmaceutics 2014;11:3322-9. [DOI: 10.1021/mp5000899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Aubert J, Begriche K, Knockaert L, Robin M, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clinics and Research in Hepatology and Gastroenterology 2011;35:630-7. [DOI: 10.1016/j.clinre.2011.04.015] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 15.7] [Reference Citation Analysis]
10 Karmakar S, Das D, Maiti A, Majumdar S, Mukherjee P, Das AS, Mitra C. Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. Phytother Res. 2011;25:1073-1081. [PMID: 21452373 DOI: 10.1002/ptr.3466] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
11 Scalera JE, Soto JA, Jara H, Ozonoff A, O'Brien M, Anderson SW. Multiexponential T(2) analyses in a murine model of hepatic fibrosis at 11.7 T MRI. NMR Biomed 2013;26:83-90. [PMID: 22674663 DOI: 10.1002/nbm.2822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
13 Collison KS, Saleh SM, Bakheet RH, Al-Rabiah RK, Inglis AL, Makhoul NJ, Maqbool ZM, Zaidi MZ, Al-Johi MA, Al-Mohanna FA. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009;17:2003-13. [PMID: 19282820 DOI: 10.1038/oby.2009.58] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
14 Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS, Shih SC. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014;20:7718-29. [PMID: 24976709 DOI: 10.3748/wjg.v20.i24.7718] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
15 Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51:3046-3054. [PMID: 20631297 DOI: 10.1194/jlr.m007096] [Cited by in Crossref: 170] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
16 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2009.12.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
17 Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. The Oncologist 2009;14:1095-105. [DOI: 10.1634/theoncologist.2009-0152] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
18 Mitry RR, De Bruyne R, Quaglia A, Hughes RD, Dhawan A. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. Hepatology 2007;46:2047-8; author reply 2048. [PMID: 18046726 DOI: 10.1002/hep.21998] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
19 Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:1087-104. [PMID: 30259536 DOI: 10.1002/hep.30294] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
20 Wu J, Chen C, Hu X, Cai X, Guan Y, Hu H, Wang Q, Chen X, Cai B, Jing X. Suppressing Cyclooxygenase-2 Prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway. Biochemical and Biophysical Research Communications 2016;469:1034-40. [DOI: 10.1016/j.bbrc.2015.12.096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
21 Choi Y, Abdelmegeed MA, Song BJ. Diet high in fructose promotes liver steatosis and hepatocyte apoptosis in C57BL/6J female mice: Role of disturbed lipid homeostasis and increased oxidative stress. Food Chem Toxicol 2017;103:111-21. [PMID: 28257781 DOI: 10.1016/j.fct.2017.02.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
22 Yeh MM. Nonalcoholic Fatty Liver Disease. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 435-40. [DOI: 10.1016/b978-0-443-06803-4.00031-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 de Castro CA, dos Santos Dias MM, da Silva KA, dos Reis SA, da Conceição LL, De Nadai Marcon L, de Sousa Moraes LF, do Carmo Gouveia Peluzio M. Liver Biomarkers and Their Applications to Nutritional Interventions in Animal Studies. In: Patel VB, Preedy VR, editors. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2017. pp. 129-52. [DOI: 10.1007/978-94-007-7675-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Ríos C, Méndez-Sánchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. J Hepatol. 2010;53:732-737. [PMID: 20594607 DOI: 10.1016/j.jhep.2010.04.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
26 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
27 Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Clin Med 2016;5:E30. [PMID: 26950158 DOI: 10.3390/jcm5030030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
28 Misciagna G, del Pilar Díaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, Chiloiro M, Abbrescia DI, Mirizzi A, Tanzi M, Caruso MG, Correale M, Reddavide R, Inguaggiato R, Cisternino AM, Osella AR. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017;21:404-12. [DOI: 10.1007/s12603-016-0809-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
29 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]
30 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe. 2010;31:225-237. [PMID: 20221762 DOI: 10.1007/s00292-010-1298-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
31 Chen X, Zhang Z, Cui B, Jiang A, Tao H, Cheng S, Liu Y. Combination of Chronic Alcohol Consumption and High-Salt Intake Elicits Gut Microbial Alterations and Liver Steatosis in Mice. J Agric Food Chem 2020;68:1750-9. [PMID: 31971384 DOI: 10.1021/acs.jafc.9b07368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Moya M, Gómez-Lechón MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 2010;184:376-87. [PMID: 20079722 DOI: 10.1016/j.cbi.2010.01.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
33 Bhatt SP, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2013;11:329-335. [PMID: 23734760 DOI: 10.1089/met.2012.0064] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
34 Boursier J, Chaigneau J, Roullier V, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Deugnier Y, Rousselet MC, Cavaro-Ménard C, Gallois Y, Aubé C, Calès P; Study group UNAM-METABOL. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. Eur J Gastroenterol Hepatol 2011;23:974-81. [PMID: 21904208 DOI: 10.1097/MEG.0b013e32834a4d82] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Remigio-Baker RA, Allison MA, Forbang NI, Loomba R, Anderson CAM, Budoff M, Schwimmer JB, Blumenthal RS, Ouyang P, Criqui MH. Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2017;258:89-96. [PMID: 28235711 DOI: 10.1016/j.atherosclerosis.2016.11.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Mohamed RA, Nabih MI, Elshobaky MB, Khattab HM. The value of noninvasive scoring systems for the diagnosis of advanced fibrosis in Egyptian patients with nonalcoholic fatty liver disease. Egypt J Intern Med 2014;26:162-9. [DOI: 10.4103/1110-7782.148151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, Bai Y, Liu Z, Yang H, Zou J, Wang H, Shi T. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomed Rep 2013;1:71-6. [PMID: 24648896 DOI: 10.3892/br.2012.27] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
38 Yang P, Wu H, Chung H, Chen C, Chi C, Yeh C, Cheng J. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn-Schmiedeberg's Arch Pharmacol 2012;385:51-6. [DOI: 10.1007/s00210-011-0691-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
40 Handzlik G, Holecki M, Kozaczka J, Kukla M, Wyskida K, Kędzierski L, Pawlicki K, Duława J. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacol Rep 2019;71:183-8. [PMID: 30780126 DOI: 10.1016/j.pharep.2018.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
41 Xie L, Yui J, Hatori A, Yamasaki T, Kumata K, Wakizaka H, Yoshida Y, Fujinaga M, Kawamura K, Zhang M. Translocator protein (18kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. Journal of Hepatology 2012;57:1076-82. [DOI: 10.1016/j.jhep.2012.07.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
42 Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297-302. [PMID: 22097893 DOI: 10.1111/j.1478-3231.2011.02639.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 12.3] [Reference Citation Analysis]
43 Xia JY, Morley TS, Scherer PE. The adipokine/ceramide axis: key aspects of insulin sensitization. Biochimie 2014;96:130-9. [PMID: 23969158 DOI: 10.1016/j.biochi.2013.08.013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
44 Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. Journal of Controlled Release 2012;161:188-97. [DOI: 10.1016/j.jconrel.2012.02.011] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 10.1] [Reference Citation Analysis]
45 Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food 2011;14:677-80. [PMID: 21688989 DOI: 10.1089/jmf.2011.0075] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
46 Canbakan B, Senturk H, Canbakan M, Toptas T, Tuncer M. Reliability of caspase activity as a biomarker of hepatic apoptosis in nonalcoholic fatty liver disease. Biomark Med 2011;5:813-5. [PMID: 22103615 DOI: 10.2217/bmm.11.70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
48 Deng Y, Palmeri ML, Rouze NC, Rosenzweig SJ, Abdelmalek MF, Nightingale KR. Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. Ultrasound Med Biol 2015;41:1948-57. [PMID: 25896024 DOI: 10.1016/j.ultrasmedbio.2015.02.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
49 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
50 Kang B, Lee SS, Cheong H, Hong SM, Jang K, Lee M. Shear Wave Elastography for Assessment of Steatohepatitis and Hepatic Fibrosis in Rat Models of Non-Alcoholic Fatty Liver Disease. Ultrasound in Medicine & Biology 2015;41:3205-15. [DOI: 10.1016/j.ultrasmedbio.2015.07.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
51 Bunnoy A, Saenphet K, Lumyong S, Saenphet S, Chomdej S. Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats. BMC Complement Altern Med 2015;15:88. [PMID: 25880551 DOI: 10.1186/s12906-015-0624-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
52 Cengiz M, Ozenirler S, Kocabiyik M. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis: . European Journal of Gastroenterology & Hepatology 2016;28:57-63. [DOI: 10.1097/meg.0000000000000502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
53 Li H, Wang L, Yan X, Liu Q, Yu C, Wei H, Li Y, Zhang X, He F, Jiang Y. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J Proteome Res 2011;10:2797-806. [PMID: 21563774 DOI: 10.1021/pr200047c] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
54 Oancea CN, Butaru AE, Streba CT, Pirici D, Rogoveanu I, Diculescu MM, Gheonea DI. Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. Rom J Morphol Embryol 2021;61:643-53. [DOI: 10.47162/rjme.61.3.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T;  Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2. [PMID: 22221544 DOI: 10.1186/1471-230x-12-2] [Cited by in Crossref: 181] [Cited by in F6Publishing: 104] [Article Influence: 18.1] [Reference Citation Analysis]
56 Pan JJ, Fisher-Hoch SP, Chen C, Feldstein AE, McCormick JB, Rahbar MH, Beretta L, Fallon MB. Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. World J Hepatol 2015; 7(11): 1586-1594 [PMID: 26085918 DOI: 10.4254/wjh.v7.i11.1586] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
57 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011;458:511-23. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1] [Reference Citation Analysis]
58 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 Belei O, Olariu L, Dobrescu A, Marcovici T, Marginean O. The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. J Pediatr Endocrinol Metab 2017;30:1161-8. [PMID: 28988228 DOI: 10.1515/jpem-2017-0252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
60 Pirhonen J, Arola J, Sädevirta S, Luukkonen P, Karppinen SM, Pihlajaniemi T, Isomäki A, Hukkanen M, Yki-Järvinen H, Ikonen E. Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. PLoS One 2016;11:e0147804. [PMID: 26808140 DOI: 10.1371/journal.pone.0147804] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
61 Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol. 2012;57:1305-1311. [PMID: 22871499 DOI: 10.1016/j.jhep.2012.07.028] [Cited by in Crossref: 135] [Cited by in F6Publishing: 115] [Article Influence: 13.5] [Reference Citation Analysis]
62 Salameh N, Larrat B, Abarca-quinones J, Pallu S, Dorvillius M, Leclercq I, Fink M, Sinkus R, Van Beers BE. Early Detection of Steatohepatitis in Fatty Rat Liver by Using MR Elastography. Radiology 2009;253:90-7. [DOI: 10.1148/radiol.2523081817] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
63 Abdelmegeed MA, Song BJ. Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev 2014;2014:149627. [PMID: 24876909 DOI: 10.1155/2014/149627] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
64 Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit 2012;18:CR735-40. [PMID: 23197236 DOI: 10.12659/msm.883601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
65 Fatouh AM, Elshafeey AH, Abdelbary A. Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. Drug Deliv Transl Res 2021. [PMID: 33948896 DOI: 10.1007/s13346-021-00993-8] [Reference Citation Analysis]
66 Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) 2014;2014:526979. [PMID: 25763333 DOI: 10.1155/2014/526979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
67 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
68 Noguchi Y, Young JD, Aleman JO, Hansen ME, Kelleher JK, Stephanopoulos G. Tracking cellular metabolomics in lipoapoptosis- and steatosis-developing liver cells. Mol Biosyst 2011;7:1409-19. [PMID: 21327189 DOI: 10.1039/c0mb00309c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
69 Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433-445. [PMID: 19604596 DOI: 10.1016/j.jhep.2009.05.023] [Cited by in Crossref: 472] [Cited by in F6Publishing: 433] [Article Influence: 36.3] [Reference Citation Analysis]
70 Morris-Stiff G, Feldstein AE. Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol 2010;53:795-6. [PMID: 20800308 DOI: 10.1016/j.jhep.2010.07.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
71 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
72 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
73 Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60:1063-1074. [PMID: 24412608 DOI: 10.1016/j.jhep.2013.12.026] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 13.6] [Reference Citation Analysis]
74 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
75 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
76 Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, Wang X, Shen JK, Peng HL. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin. 2009;30:1505-1512. [PMID: 19890358 DOI: 10.1038/aps.2009.150] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
77 Huang H, Wang J, Xu L, Miao M, Xu C. Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Int J Endocrinol 2021;2021:6676526. [PMID: 34194492 DOI: 10.1155/2021/6676526] [Reference Citation Analysis]
78 Choi Y, Lee JM, Yi NJ, Kim H, Park MS, Hong G, Yoo T, Suh SW, Lee HW, Lee KW, Suh KS. Heterogeneous living donor hepatic fat distribution on MRI chemical shift imaging. Ann Surg Treat Res 2015;89:37-42. [PMID: 26131443 DOI: 10.4174/astr.2015.89.1.37] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
79 Hua B, Hakkarainen A, Zhou Y, Lundbom N, Yki-järvinen H. Fat accumulates preferentially in the right rather than the left liver lobe in non-diabetic subjects. Digestive and Liver Disease 2018;50:168-74. [DOI: 10.1016/j.dld.2017.08.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:257-268. [PMID: 20842510 DOI: 10.1007/s00535-010-0305-6] [Cited by in Crossref: 131] [Cited by in F6Publishing: 116] [Article Influence: 10.9] [Reference Citation Analysis]
81 Darweesh SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, Fathi SA, Attia D, AbdAllah M. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. Eur J Gastroenterol Hepatol. 2019;31:633-641. [PMID: 30839434 DOI: 10.1097/meg.0000000000001385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
82 Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282-1293. [PMID: 19637286 DOI: 10.1002/hep.23119] [Cited by in Crossref: 181] [Cited by in F6Publishing: 159] [Article Influence: 13.9] [Reference Citation Analysis]
83 Zhou YY, Zhou XD, Wu SJ, Hu XQ, Tang B, Poucke SV, Pan XY, Wu WJ, Gu XM, Fu SW, Zheng MH. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2018;30:631-6. [PMID: 29351115 DOI: 10.1097/MEG.0000000000001075] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
84 Nakamura A, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Okanoue T, Nakajima A, Maeda S, Terauchi Y. Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2013;4:651-658. [PMID: 24843721 DOI: 10.1111/jdi.12101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
86 Bantel H, Bahr MJ, Schulze-osthoff K. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis. Hepatology 2009;50:991-991. [DOI: 10.1002/hep.23092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
87 Mannery YO, McClain CJ, Vos MB. Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev 2011;7:310-5. [PMID: 25346653 DOI: 10.2174/157339611796892364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Arya V, Bansal M, Girard L, Arya S, Valluri A. Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review. Case Rep Dermatol 2010;2:156-64. [PMID: 21076689 DOI: 10.1159/000320207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
89 da Silva LCM, de Oliveira JT, Tochetto S, de Oliveira CPMS, Sigrist R, Chammas MC. Ultrasound elastography in patients with fatty liver disease. Radiol Bras 2020;53:47-55. [PMID: 32313337 DOI: 10.1590/0100-3984.2019.0028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems: . European Journal of Gastroenterology & Hepatology 2010. [DOI: 10.1097/meg.0b013e32832ca0cb] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
91 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
92 Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16:141-149. [PMID: 19262374 DOI: 10.1097/med.0b013e3283293015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
93 Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;4:517-24. [PMID: 24843703 DOI: 10.1111/jdi.12107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
94 Miyake T, Matsuura B, Furukawa S, Yoshida O, Hirooka M, Kumagi T, Ishihara T, Kanzaki S, Nakaguchi H, Miyazaki M, Nakamura Y, Yamamoto Y, Koizumi Y, Tokumoto Y, Takeshita E, Ikeda Y, Abe M, Kitai K, Hiasa Y. Nonalcoholic fatty liver disease is a risk factor for glucose intolerance onset in men regardless of alanine aminotransferase status. J Diabetes Investig 2021. [PMID: 33742744 DOI: 10.1111/jdi.13548] [Reference Citation Analysis]
95 Giudice EM, Grandone A, Cirillo G, Santoro N, Amato A, Brienza C, Savarese P, Marzuillo P, Perrone L. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One. 2011;6:e27933. [PMID: 22140488 DOI: 10.1371/journal.pone.0027933] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
96 Ariz U, Mato JM, Lu SC, Martínez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods Mol Biol. 2010;593:109-136. [PMID: 19957147 DOI: 10.1007/978-1-60327-194-3_6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
97 Li KK, Neuberger J. Recurrent nonviral liver disease following liver transplantation. Expert Rev Gastroenterol Hepatol. 2009;3:257-268. [PMID: 19485808 DOI: 10.1586/egh.09.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
98 Lee SJ, Kang JH, Choi SY, Suk KT, Kim DJ, Kwon OS. PKCδ as a regulator for TGFβ1-induced α-SMA production in a murine nonalcoholic steatohepatitis model. PLoS One 2013;8:e55979. [PMID: 23441159 DOI: 10.1371/journal.pone.0055979] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
99 Pihlajamäki J, Kuulasmaa T, Kaminska D, Simonen M, Kärjä V, Grönlund S, Käkelä P, Pääkkönen M, Kainulainen S, Punnonen K. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2012;56:663-670. [PMID: 22027586 DOI: 10.1016/j.jhep.2011.10.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
100 Cengiz M, Candır BA, Yılmaz G, Akyol G, Ozenirler S. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage? World J Gastroenterol 2013; 19(42): 7412-7418 [PMID: 24259972 DOI: 10.3748/wjg.v19.i42.7412] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
101 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
102 Noguchi Y, Young JD, Aleman JO, Hansen ME, Kelleher JK, Stephanopoulos G. Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis. J Biol Chem 2009;284:33425-36. [PMID: 19758988 DOI: 10.1074/jbc.M109.049478] [Cited by in Crossref: 50] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
103 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
104 Alwahsh SM, Xu M, Seyhan HA, Ahmad S, Mihm S, Ramadori G, Schultze FC. Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. World J Gastroenterol 2014; 20(7): 1807-1821 [PMID: 24587658 DOI: 10.3748/wjg.v20.i7.1807] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
105 Dietrich CG, Götze O, Geier A. Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World J Gastroenterol 2016; 22(1): 72-88 [PMID: 26755861 DOI: 10.3748/wjg.v22.i1.72] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
106 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(5): 274-283 [PMID: 24868321 DOI: 10.4254/wjh.v6.i5.274] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 20.0] [Reference Citation Analysis]
107 Nakata R, Hyodo F, Murata M, Eto H, Nakaji T, Kawano T, Narahara S, Yasukawa K, Akahoshi T, Tomikawa M, Hashizume M. In vivo redox metabolic imaging of mitochondria assesses disease progression in non-alcoholic steatohepatitis. Sci Rep 2017;7:17170. [PMID: 29215054 DOI: 10.1038/s41598-017-17447-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
108 Sim M, Ham JR, Lee H, Seo K, Lee M. Long-term supplementation of umbelliferone and 4-methylumbelliferone alleviates high-fat diet induced hypertriglyceridemia and hyperglycemia in mice. Chemico-Biological Interactions 2014;216:9-16. [DOI: 10.1016/j.cbi.2014.03.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
109 Ulukaya E, Yilmaz Y, Moshkovskii S, Karpova M, Pyatnitskiy M, Atug O, Dolar E. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol. 2009;44:1471-1476. [PMID: 19883279 DOI: 10.3109/00365520903353379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
110 de Jonge C, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, Greve JW. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:1517-20. [PMID: 23920034 DOI: 10.1016/j.cgh.2013.07.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
111 Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. [PMID: 25216184 DOI: 10.1371/journal.pone.0107584] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
112 Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010;16:4784-4791. [PMID: 20939106 DOI: 10.3748/wjg.v16i38.4784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Yang HR. Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease. Korean J Pediatr 2013;56:45-51. [PMID: 23482433 DOI: 10.3345/kjp.2013.56.2.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. [PMID: 24648894 DOI: 10.3892/br.2018.18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 2014; 20(39): 14172-14184 [PMID: 25339805 DOI: 10.3748/wjg.v20.i39.14172] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
116 Lee JS, Zheng Z, Mendez R, Ha SW, Xie Y, Zhang K. Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model. Toxicol Lett 2012;211:29-38. [PMID: 22414386 DOI: 10.1016/j.toxlet.2012.02.017] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
117 González Jiménez E, Schmidt Río-Valle J, Álvarez Ferre J. [Fatty liver and its clinical management in obese adolescents]. Endocrinol Nutr 2011;58:32-7. [PMID: 21216209 DOI: 10.1016/j.endonu.2010.10.005] [Reference Citation Analysis]
118 Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335. [PMID: 21254180 DOI: 10.1002/hep.24013] [Cited by in Crossref: 272] [Cited by in F6Publishing: 248] [Article Influence: 22.7] [Reference Citation Analysis]
119 Yuan F, Song B, Huang Z, Xia C, Liu X. Quantification of pancreatic fat with dual-echo imaging at 3.0-T MR in clinical application: how do the corrections for T1 and T2* relaxation effect work and simplified correction strategy. Acta Radiol 2018;59:1021-8. [PMID: 29260576 DOI: 10.1177/0284185117745908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
120 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
121 Wang X, Sugimoto K, Fujisawa T, Shindo N, Minato S, Kamada Y, Hamano M, Ohishi M, Ikegami H, Rakugi H. Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse. Hepatol Res. 2014;44:102-113. [PMID: 23510093 DOI: 10.1111/hepr.12092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
122 Marzuillo P, Grandone A, Perrone L, Miraglia del Giudice E. Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21(21): 6444-6450 [PMID: 26074683 DOI: 10.3748/wjg.v21.i21.6444] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
123 Sumida Y, Yonei Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Hibino S, Yamaguchi K, Mitsuyoshi H. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2010;40:901-910. [PMID: 20887595 DOI: 10.1111/j.1872-034x.2010.00704.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
124 Tannapfel A, Denk H, Dienes H, Langner C, Schirmacher P, Trauner M, Flott-rahmel B. Histopathologische Diagnose der nichtalkoholischen und alkoholischen Fettlebererkrankung: Konsensusbasierte Leitlinie der Stufe 2. Pathologe 2010;31:225-37. [DOI: 10.1007/s00292-010-1274-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
125 Palmer M. Nonalcoholic Fatty Liver Disease. In: Mullin GE, Cheskin LJ, Matarese LE, editors. Integrative Weight Management. New York: Springer; 2014. pp. 145-69. [DOI: 10.1007/978-1-4939-0548-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
126 Feldstein AE, Nobili V. Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. J Pediatr Gastroenterol Nutr 2010;51:378-9. [PMID: 20808243 DOI: 10.1097/MPG.0b013e3181ecf3d4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
127 Guiu B, Crevisy-girod E, Binquet C, Duvillard L, Masson D, Lepage C, Hamza S, Krausé D, Verges B, Minello A, Cercueil J, Hillon P, Petit J. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol 2012;22:855-63. [DOI: 10.1007/s00330-011-2326-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
128 Di Mauro S, Ragusa M, Urbano F, Filippello A, Di Pino A, Scamporrino A, Pulvirenti A, Ferro A, Rabuazzo A, Purrello M, Purrello F, Piro S. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications. Nutrition, Metabolism and Cardiovascular Diseases 2016;26:1129-39. [DOI: 10.1016/j.numecd.2016.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
129 Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal. 2011;15:505-521. [PMID: 21128705 DOI: 10.1089/ars.2010.3790] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
130 He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, Yuan F. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2017;2017:9729107. [PMID: 28326329 DOI: 10.1155/2017/9729107] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
131 Kayadibi H, Gültepe M, Yasar B, Ince AT, Ozcan O, Ipcioglu OM, Kurdas OO, Bolat B, Benek YZ, Guveli H. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci. 2009;54:1764-1771. [PMID: 18989777 DOI: 10.1007/s10620-008-0535-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
132 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
133 Abdel-Razik A, Mousa N, Shabana W, Refaey M, ElMahdy Y, Elhelaly R, Elzehery R, Zalata K, Arafa M, Elbaz S, Hafez M, Awad M. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study. Eur J Gastroenterol Hepatol. 2016;28:e1-9. [PMID: 26469357 DOI: 10.1097/meg.0000000000000486] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
134 Fu JF, Shi HB, Liu LR, Jiang P, Liang L, Wang CL, Liu XY. Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children? World J Gastroenterol 2011; 17(6): 735-742 [PMID: 21390143 DOI: 10.3748/wjg.v17.i6.735] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
135 Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, (JSG-NAFLD) TOJSGON. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(29): 10108-10114 [PMID: 25110437 DOI: 10.3748/wjg.v20.i29.10108] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
136 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(42): 5286-5296 [PMID: 21072891 DOI: 10.3748/wjg.v16.i42.5286] [Cited by in CrossRef: 230] [Cited by in F6Publishing: 210] [Article Influence: 19.2] [Reference Citation Analysis]
138 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
139 Zhang Z, Chen X, Cui B. Modulation of the fecal microbiome and metabolome by resistant dextrin ameliorates hepatic steatosis and mitochondrial abnormalities in mice. Food Funct 2021;12:4504-18. [PMID: 33885128 DOI: 10.1039/d1fo00249j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1902] [Article Influence: 205.7] [Reference Citation Analysis]
141 Kalantari H, Moradi F, Hassanzade A. Association between sonographic diagnosis of fatty liver with histopathologic abnormalities and liver biopsy findings in middle age patient with non-alcoholic fatty liver disease. Adv Biomed Res 2016;5:122. [PMID: 27563632 DOI: 10.4103/2277-9175.186985] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
142 Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, Diehl AM, Nightingale KR. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011;55:666-72. [PMID: 21256907 DOI: 10.1016/j.jhep.2010.12.019] [Cited by in Crossref: 246] [Cited by in F6Publishing: 203] [Article Influence: 22.4] [Reference Citation Analysis]
143 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
144 Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008;29:939-60. [DOI: 10.1210/er.2008-0009] [Cited by in Crossref: 338] [Cited by in F6Publishing: 318] [Article Influence: 24.1] [Reference Citation Analysis]
145 Cha JY, Kim YB. Sulfated oxysterol 25HC3S as a therapeutic target of non-alcoholic fatty liver disease. Metabolism 2012;61:1055-7. [PMID: 22592130 DOI: 10.1016/j.metabol.2012.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
146 Garza AL, Vatcheva KP, Pan JJ, Rahbar MH, Fallon MB, McCormick JB, Fisher-Hoch SP. Liver and Other Gastrointestinal Cancers Are Frequent in Mexican Americans. J Racial Ethn Health Disparities 2016;3:1-10. [PMID: 26896100 DOI: 10.1007/s40615-015-0104-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
147 Paiva AA, Raposo HF, Wanschel AC, Nardelli TR, Oliveira HC. Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death. Oxid Med Cell Longev 2017;2017:1838679. [PMID: 28163820 DOI: 10.1155/2017/1838679] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
148 Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, Wilson MD, Willingham MC, Rudel LL. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem 2010;285:14267-74. [PMID: 20231283 DOI: 10.1074/jbc.M110.118422] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
149 Lee MM, Kim HG, Lee SB, Lee JS, Kim WY, Choi SH, Lee SK, Byun CK, Hyun PM, Son CG. CGplus, a standardized herbal composition ameliorates non-alcoholic steatohepatitis in a tunicamycin-induced mouse model. Phytomedicine 2018;41:24-32. [PMID: 29519316 DOI: 10.1016/j.phymed.2018.01.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
150 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013;4:51-63. [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 77] [Article Influence: 10.9] [Reference Citation Analysis]
151 Boga S, Koksal AR, Alkim H, Yilmaz Ozguven MB, Bayram M, Ergun M, Sisman G, Tekin Neijmann S, Alkim C. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metab Syndr Relat Disord. 2015;13:393-399. [PMID: 26367098 DOI: 10.1089/met.2015.0046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
152 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
153 Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14(41): 6395-6400 [PMID: 19009658 DOI: 10.3748/wjg.14.6395] [Cited by in CrossRef: 131] [Cited by in F6Publishing: 130] [Article Influence: 9.4] [Reference Citation Analysis]
154 Fang J, Zhou Z, Chang NF, Wan YL, Tsui PH. Ultrasound parametric imaging of hepatic steatosis using the homodyned-K distribution: An animal study. Ultrasonics 2018;87:91-102. [PMID: 29476945 DOI: 10.1016/j.ultras.2018.02.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
155 Leamy AK, Hasenour CM, Egnatchik RA, Trenary IA, Yao CH, Patti GJ, Shiota M, Young JD. Knockdown of triglyceride synthesis does not enhance palmitate lipotoxicity or prevent oleate-mediated rescue in rat hepatocytes. Biochim Biophys Acta 2016;1861:1005-14. [PMID: 27249207 DOI: 10.1016/j.bbalip.2016.05.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
156 Scott CH, Cha KM, Ngai J, Jiang C, Cheng K, Stokes RA, Ho KWK, George J, Gonzalez FJ, Gunton JE. Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. PLoS One 2017;12:e0186543. [PMID: 29190746 DOI: 10.1371/journal.pone.0186543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
157 Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008;19:567-76. [PMID: 18430557 DOI: 10.1016/j.jnutbio.2007.10.001] [Cited by in Crossref: 145] [Cited by in F6Publishing: 142] [Article Influence: 10.4] [Reference Citation Analysis]
158 do Nascimento JH, Epifanio M, Soder RB, Baldisserotto M. MRI-diagnosed nonalcoholic fatty liver disease is correlated to insulin resistance in adolescents. Acad Radiol 2013;20:1436-42. [PMID: 24119357 DOI: 10.1016/j.acra.2013.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
159 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. [DOI: 10.1017/s0029665110000030] [Cited by in Crossref: 141] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
160 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. [PMID: 24648894 DOI: 10.3892/br.2012.18] [Cited by in Crossref: 107] [Cited by in F6Publishing: 110] [Article Influence: 10.7] [Reference Citation Analysis]
161 Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, Fu SW, Zheng MH. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun 2018;2:376-92. [PMID: 29619417 DOI: 10.1002/hep4.1155] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
162 Elalfy H, Besheer T, Elhammady D, Mohamed MA, El-hussiny MA, Elkashef W, El-deek BS, Mohamed Alsayed SA. Model for Non-Invasive Diagnosis of NAFLD Incorporating Caspase 3-Cleaved Cytokeratin-18: A Clinical, Serological, and Immunohistochemical Analysis. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.60168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, Leebeek FW, Hofman A, Stricker BH, Castera L, Janssen HL. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology. 2016;63:138-147. [PMID: 26171685 DOI: 10.1002/hep.27981] [Cited by in Crossref: 148] [Cited by in F6Publishing: 132] [Article Influence: 21.1] [Reference Citation Analysis]
164 Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 2010;34:1255-64. [DOI: 10.1038/ijo.2010.40] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 5.9] [Reference Citation Analysis]
165 Bullón-vela MV, Abete I, Alfredo Martínez J, Angeles Zulet M. Obesity and Nonalcoholic Fatty Liver Disease. Obesity. Elsevier; 2018. pp. 111-33. [DOI: 10.1016/b978-0-12-812504-5.00006-4] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072-1078. [PMID: 19585618 DOI: 10.1002/hep.23050] [Cited by in Crossref: 450] [Cited by in F6Publishing: 403] [Article Influence: 34.6] [Reference Citation Analysis]
167 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
168 Unal E, Idilman IS, Karçaaltıncaba M. Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era. Expert Rev Gastroenterol Hepatol 2017;11:167-82. [PMID: 27937040 DOI: 10.1080/17474124.2017.1271710] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
169 Fatouh AM, Elshafeey AH, Abdelbary A. Galactosylated Chitosan Coated Liposomes of Ledipasvir for Liver Targeting: Chemical Synthesis, Statistical Optimization, In-vitro and In-vivo evaluation. J Pharm Sci 2021;110:1148-59. [PMID: 33039437 DOI: 10.1016/j.xphs.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Andrade BF, Braga CP, Dos Santos KC, Barbosa LN, Rall VL, Sforcin JM, Fernandes AA, Fernandes Júnior A. Effect of Inhaling Cymbopogon martinii Essential Oil and Geraniol on Serum Biochemistry Parameters and Oxidative Stress in Rats. Biochem Res Int 2014;2014:493183. [PMID: 25574396 DOI: 10.1155/2014/493183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
171 Xu WS, Qiu XM, Ou QS, Liu C, Lin JP, Chen HJ, Lin S, Wang WH, Lin SR, Chen J. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine (Baltimore). 2015;94:e612. [PMID: 25761184 DOI: 10.1097/md.0000000000000612] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
172 Pang S, Dong W, Liu N, Gao S, Li J, Zhang X, Lu D, Zhang L. Diallyl sulfide protects against dilated cardiomyopathy via inhibition of oxidative stress and apoptosis in mice. Mol Med Rep 2021;24:852. [PMID: 34651661 DOI: 10.3892/mmr.2021.12492] [Reference Citation Analysis]
173 Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol. 2011;9:150-155. [PMID: 20888433 DOI: 10.1016/j.cgh.2010.09.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
174 Gentile CL, Frye MA, Pagliassotti MJ. Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 2011;37:8-16. [PMID: 21328622 DOI: 10.1002/biof.135] [Cited by in Crossref: 97] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
175 Mahran HN, Saber LM, Alghaithy AA, Elareefy AA. The role of elevated alanine aminotransferase (ALT), FasL and atherogenic dyslipidemia in type II diabetes mellitus. J Taibah Univ Med Sci 2017;12:8-13. [PMID: 31435207 DOI: 10.1016/j.jtumed.2016.10.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Hossain IA, Akter S, Bhuiyan FR, Shah MR, Rahman MK, Ali L. Subclinical inflammation in relation to insulin resistance in prediabetic subjects with nonalcoholic fatty liver disease. BMC Res Notes. 2016;9:266. [PMID: 27169860 DOI: 10.1186/s13104-016-2071-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
177 Kim KY, Song JS, Kannengiesser S, Han YM. Hepatic fat quantification using the proton density fat fraction (PDFF): utility of free-drawn-PDFF with a large coverage area. Radiol Med 2015;120:1083-93. [PMID: 25952293 DOI: 10.1007/s11547-015-0545-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
178 Parker HM, Johnson NA, Burdon CA, Cohn JS, O’connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology 2012;56:944-51. [DOI: 10.1016/j.jhep.2011.08.018] [Cited by in Crossref: 339] [Cited by in F6Publishing: 309] [Article Influence: 33.9] [Reference Citation Analysis]
179 Harrison SA. Abnormal liver tests and fatty liver on ultrasound. Clin Gastroenterol Hepatol 2008;6:26-9. [PMID: 18166475 DOI: 10.1016/j.cgh.2007.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
180 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
181 Li B, Jara H, Yu H, O'Brien M, Soto J, Anderson SW. Enhanced Laws textures: A potential MRI surrogate marker of hepatic fibrosis in a murine model. Magn Reson Imaging 2017;37:33-40. [PMID: 27856399 DOI: 10.1016/j.mri.2016.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
182 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
183 Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009; 15(35): 4387-4391 [PMID: 19764089 DOI: 10.3748/wjg.15.4387] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
184 Barry B, Buch K, Soto JA, Jara H, Nakhmani A, Anderson SW. Quantifying liver fibrosis through the application of texture analysis to diffusion weighted imaging. Magnetic Resonance Imaging 2014;32:84-90. [DOI: 10.1016/j.mri.2013.04.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
185 Peng XG, Ju S, Qin Y, Fang F, Cui X, Liu G, Ni Y, Teng GJ. Quantification of liver fat in mice: comparing dual-echo Dixon imaging, chemical shift imaging, and 1H-MR spectroscopy. J Lipid Res 2011;52:1847-55. [PMID: 21737754 DOI: 10.1194/jlr.D016691] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
186 Senoo H, Mezaki Y, Fujiwara M. The stellate cell system (vitamin A-storing cell system). Anat Sci Int. 2017;92:387-455. [PMID: 28299597 DOI: 10.1007/s12565-017-0395-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
187 McCullough A, Previs S, Kasumov T. Stable isotope-based flux studies in nonalcoholic fatty liver disease. Pharmacol Ther 2018;181:22-33. [PMID: 28720429 DOI: 10.1016/j.pharmthera.2017.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
188 Ilan Y. A fourth dimension in decision making in hepatology. Hepatol Res 2010;40:1143-54. [PMID: 20973886 DOI: 10.1111/j.1872-034X.2010.00737.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
189 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
190 Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res. 2010;67:665-670. [PMID: 20496475 DOI: 10.1203/pdr.0b013e3181da4798] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
191 Yoon MY, Sung JM, Song CS, Lee WY, Rhee EJ, Shin JH, Yoo CH, Chae SW, Kim JY, Jin W, Cho YK. Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. Clin Mol Hepatol 2012;18:279-86. [PMID: 23091808 DOI: 10.3350/cmh.2012.18.3.279] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
192 Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698. [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077] [Cited by in Crossref: 233] [Cited by in F6Publishing: 228] [Article Influence: 16.6] [Reference Citation Analysis]
193 Imajo K, Yoneda M, Fujita K, Kessoku T, Tomeno W, Ogawa Y, Shinohara Y, Sekino Y, Mawatari H, Nozaki Y, Kirikoshi H, Taguri M, Toshima G, Takahashi J, Saito S, Wada K, Nakajima A. Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J Gastroenterol 2014;49:295-304. [PMID: 23503837 DOI: 10.1007/s00535-013-0776-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
194 Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol 2015;7:121-7. [PMID: 26316434 DOI: 10.4274/jcrpe.1749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
195 Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Annals of Hepatology 2009;8:S25-33. [DOI: 10.1016/s1665-2681(19)31823-x] [Cited by in Crossref: 27] [Article Influence: 2.1] [Reference Citation Analysis]
196 Blüher M, Tönjes A, Stumvoll M. Does retinol‐binding protein 4 cause or reflect fatty liver disease? Hepatology 2008;48:4-6. [DOI: 10.1002/hep.22426] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
197 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Wang Q, Jiang L, Wang J, Li S, Yu Y, You J, Zeng R, Gao X, Rui L, Li W, Liu Y. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology 2009;49:1166-75. [PMID: 19177596 DOI: 10.1002/hep.22774] [Cited by in Crossref: 118] [Cited by in F6Publishing: 118] [Article Influence: 9.1] [Reference Citation Analysis]
199 Xiong QF, Xie YT. RNA interference-mediated silencing of the FoxO3a gene inhibits palmitate-induced apoptosis in human hepatoma cell line HepG2.2.15. Shijie Huaren Xiaohua Zazhi 2011; 19(25): 2623-2628 [DOI: 10.11569/wcjd.v19.i25.2623] [Reference Citation Analysis]
200 Boyraz M, Hatipoğlu N, Sarı E, Akçay A, Taşkın N, Ulucan K, Akçay T. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obesity Research & Clinical Practice 2014;8:e356-63. [DOI: 10.1016/j.orcp.2013.08.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
201 Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19:1313-1323. [PMID: 19693638 DOI: 10.1007/s11695-009-9912-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
202 Miyake T, Kumagi T, Hirooka M, Furukawa S, Kawasaki K, Koizumi M, Todo Y, Yamamoto S, Nunoi H, Tokumoto Y. Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study. J Gastroenterol. 2015;50:230-237. [PMID: 24748332 DOI: 10.1007/s00535-014-0959-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
203 Masuda K, Ono M, Fukumoto M, Hirose A, Munekage K, Ochi T, Okamoto N, Akagi N, Ogawa Y, Saibara T. Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. Hepatol Res. 2012;42:273-279. [PMID: 22251279 DOI: 10.1111/j.1872-034x.2011.00923.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
204 Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9:152-61. [DOI: 10.1038/nrgastro.2011.273] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
205 Lin J, Lu F, Zheng W, Xu S, Tai D, Yu H, Huang Z. Assessment of liver steatosis and fibrosis in rats using integrated coherent anti-Stokes Raman scattering and multiphoton imaging technique. J Biomed Opt 2011;16:116024. [PMID: 22112129 DOI: 10.1117/1.3655353] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
206 Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013;2013:450639. [PMID: 23653642 DOI: 10.1155/2013/450639] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
207 Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Van Gaal L, Michielsen P. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol. 2010;22:1449-1457. [PMID: 21389796 DOI: 10.1097/meg.0b013e32833f14a1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
208 Helajärvi H, Pahkala K, Heinonen OJ, Juonala M, Oikonen M, Tammelin T, Hutri-Kähönen N, Kähönen M, Lehtimäki T, Mikkilä V. Television viewing and fatty liver in early midlife. The Cardiovascular Risk in Young Finns Study. Ann Med. 2015;47:519-526. [PMID: 26362414 DOI: 10.3109/07853890.2015.1077989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
209 Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol. 2009;193:14-27. [PMID: 19542391 DOI: 10.2214/ajr.09.2601] [Cited by in Crossref: 128] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
210 Rutigliano I, Vinci R, De Filippo G, Mancini M, Stoppino L, d'Apolito M, Giardino I, Macarini L, Pettoello Mantovani M, Campanozzi A. Metabolic syndrome, hepatic steatosis, and cardiovascular risk in children. Nutrition 2017;36:1-7. [PMID: 28336101 DOI: 10.1016/j.nut.2016.10.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
211 Tevar AD, Clarke C, Wang J, Rudich SM, Woodle ES, Lentsch AB, Edwards ML. Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg. 2010;210:515-526. [PMID: 20347746 DOI: 10.1016/j.jamcollsurg.2010.01.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
212 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
213 Suzuki K, Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Nozaki Y, Takahashi H, Abe Y, Inamori M, Shimamura T. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res. 2010;40:693-700. [PMID: 20412325 DOI: 10.1111/j.1872-034x.2010.00643.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
214 Anderson SW, Jara H, Ozonoff A, O'brien M, Hamilton JA, Soto JA. Effect of disease progression on liver apparent diffusion coefficient and T2 values in a murine model of hepatic fibrosis at 11.7 Tesla MRI. J Magn Reson Imaging 2012;35:140-6. [DOI: 10.1002/jmri.22807] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
215 Walenbergh SM, Houben T, Rensen SS, Bieghs V, Hendrikx T, van Gorp PJ, Oligschlaeger Y, Jeurissen ML, Gijbels MJ, Buurman WA, Vreugdenhil AC, Greve JW, Plat J, Hofker MH, Kalhan S, Pihlajamäki J, Lindsey P, Koek GH, Shiri-Sverdlov R. Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. Sci Rep 2016;6:38278. [PMID: 27922112 DOI: 10.1038/srep38278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
216 Li XH, Zhu J, Zhang XM, Ji YF, Chen TW, Huang XH, Yang L, Zeng NL. Abdominal MRI at 3.0 T: LAVA-flex compared with conventional fat suppression T1-weighted images: LAVA-Flex Compared with FSPGR Images. J Magn Reson Imaging 2014;40:58-66. [DOI: 10.1002/jmri.24329] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
217 Pastuszak M, Groszewski K, Pastuszak M, Dyrla P, Wojtuń S, Gil J. Cytokeratins in gastroenterology. Systematic review. Prz Gastroenterol 2015;10:61-70. [PMID: 26557935 DOI: 10.5114/pg.2015.51182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
218 Cusi K. The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity. In: Regensteiner JG, Reusch JE, Stewart KJ, Veves A, editors. Diabetes and Exercise. Totowa: Humana Press; 2009. pp. 3-54. [DOI: 10.1007/978-1-59745-260-1_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
219 Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20:143-153. [PMID: 24976277 DOI: 10.4103/1319-3767.132983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
220 Foster MT, Gentile CL, Cox-york K, Wei Y, Wang D, Estrada AL, Reese L, Miller T, Pagliassotti MJ, Weir TL. Fuzhuan tea consumption imparts hepatoprotective effects and alters intestinal microbiota in high saturated fat diet-fed rats. Mol Nutr Food Res 2016;60:1213-20. [DOI: 10.1002/mnfr.201500654] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
221 Amacher DE. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 2014;19:541-52. [PMID: 25189636 DOI: 10.3109/1354750X.2014.958535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
222 Öner-İyidoğan Y, Koçak H, Seyidhanoğlu M, Gürdöl F, Gülçubuk A, Yildirim F, Çevik A, Uysal M. Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet. J Physiol Biochem 2013;69:677-86. [PMID: 23430567 DOI: 10.1007/s13105-013-0244-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
223 Talwalkar JA. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology 2009;50:1000-3. [PMID: 19787817 DOI: 10.1002/hep.23288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
224 Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, Feldstein AE. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008;6:1249-54. [PMID: 18995215 DOI: 10.1016/j.cgh.2008.07.016] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 8.1] [Reference Citation Analysis]
225 Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, Masson D, Hillon P, Krause D, Cercueil JP. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology. 2009;250:95-102. [PMID: 19092092 DOI: 10.1148/radiol.2493080217] [Cited by in Crossref: 138] [Cited by in F6Publishing: 132] [Article Influence: 10.6] [Reference Citation Analysis]
226 Fan JG. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 2008;9:63-7. [PMID: 18419637 DOI: 10.1111/j.1751-2980.2008.00323.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
227 Thomson SJ, Westlake S, Rahman TM, Cowan ML, Majeed A, Maxwell JD, Kang JY. Chronic liver disease--an increasing problem: a study of hospital admission and mortality rates in England, 1979-2005, with particular reference to alcoholic liver disease. Alcohol Alcohol. 2008;43:416-422. [PMID: 18385412 DOI: 10.1093/alcalc/agn020] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
228 Lu Z, Ma H, Xu C, Shao Z, Cen C, Li Y. Serum Sialic Acid Level Is Significantly Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: A Cross-Sectional Study. Biomed Res Int 2016;2016:5921589. [PMID: 27042666 DOI: 10.1155/2016/5921589] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
229 De Minicis S, Seki E, Paik YH, Osterreicher CH, Kodama Y, Kluwe J, Torozzi L, Miyai K, Benedetti A, Schwabe RF. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology. 2010;52:1420-1430. [PMID: 20690191 DOI: 10.1002/hep.23804] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
230 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
231 Jee SJ, Kim YJ, Song SY, Paik SS. Association among Histopathology, Clinical Manifestation, and Ultrasonographic Grades in Pediatric Non-alcoholic Fatty Liver Disease. Korean J Gastroenterol 2011;57:158. [DOI: 10.4166/kjg.2011.57.3.158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Denzer C. [Non-alcoholic fatty liver disease in obese children and adolescents]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56:517-27. [PMID: 23529597 DOI: 10.1007/s00103-012-1639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
233 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 238] [Article Influence: 24.5] [Reference Citation Analysis]
234 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
235 Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008;28:503-22. [DOI: 10.1111/j.1365-2036.2008.03752.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
236 Matsuzaka T, Atsumi A, Matsumori R, Nie T, Shinozaki H, Suzuki-Kemuriyama N, Kuba M, Nakagawa Y, Ishii K, Shimada M. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology. 2012;56:2199-2208. [PMID: 22753171 DOI: 10.1002/hep.25932] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 12.3] [Reference Citation Analysis]
237 Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-ayuso RM, González R, Alvarez M, Hernández V, García-zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver International 2009;29:82-8. [DOI: 10.1111/j.1478-3231.2008.01823.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
238 Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010; 16(38): 4784-4791 [PMID: 20939106 DOI: 10.3748/wjg.v16.i38.4784] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
239 Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 2013;13:40. [PMID: 23530957 DOI: 10.1186/1471-2431-13-40] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]
240 Jamali R. Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity. Thrita J Med Sci 2013;2:43-51. [DOI: 10.5812/thrita.11795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
241 Houben T, Brandsma E, Walenbergh SMA, Hofker MH, Shiri-Sverdlov R. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862:416-29. [PMID: 27472963 DOI: 10.1016/j.bbalip.2016.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
242 Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, Casini A. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr. 2010;61:792-802. [PMID: 20465434 DOI: 10.3109/09637486.2010.487480] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 6.8] [Reference Citation Analysis]
243 Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, Feldstein AE. Retinol-Binding Protein 4: A Promising Circulating Marker of Liver Damage in Pediatric Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2009;7:575-9. [DOI: 10.1016/j.cgh.2008.12.031] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
244 Kim A, Yang HR, Cho JM, Chang JY, Moon JS, Ko JS. A Nomogram for Predicting Non-Alcoholic Fatty Liver Disease in Obese Children. Pediatr Gastroenterol Hepatol Nutr 2020;23:276-85. [PMID: 32483549 DOI: 10.5223/pghn.2020.23.3.276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009;50:1113-20. [PMID: 19637190 DOI: 10.1002/hep.23133] [Cited by in Crossref: 134] [Cited by in F6Publishing: 123] [Article Influence: 10.3] [Reference Citation Analysis]
246 Zhang J, Li Y, Jiang S, Yu H, An W. Enhanced endoplasmic reticulum SERCA activity by overexpression of hepatic stimulator substance gene prevents hepatic cells from ER stress-induced apoptosis. Am J Physiol Cell Physiol. 2014;306:C279-C290. [PMID: 24284796 DOI: 10.1152/ajpcell.00117.2013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
247 Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58:801-810. [PMID: 23183522 DOI: 10.1016/j.jhep.2012.11.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
248 do Nascimento JH, Soder RB, Epifanio M, Baldisserotto M. Accuracy of computer-aided ultrasound as compared with magnetic resonance imaging in the evaluation of nonalcoholic fatty liver disease in obese and eutrophic adolescents. Radiol Bras 2015;48:225-32. [PMID: 26379321 DOI: 10.1590/0100-3984.2014.0074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
249 Jindal R, Patel SJ, Yarmush ML. Tissue-engineered model for real-time monitoring of liver inflammation. Tissue Eng Part C Methods 2011;17:113-22. [PMID: 20684748 DOI: 10.1089/ten.TEC.2009.0782] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
250 Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology 2012;55:1292-5. [PMID: 22461076 DOI: 10.1002/hep.24767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
251 Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-1117. [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
252 Fang J, Chang NF, Tsui PH. Performance Evaluations on Using Entropy of Ultrasound Log-Compressed Envelope Images for Hepatic Steatosis Assessment: An In Vivo Animal Study. Entropy (Basel) 2018;20:E120. [PMID: 33265211 DOI: 10.3390/e20020120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
253 Nilsson H, Karlgren S, Blomqvist L, Jonas E. The inhomogeneous distribution of liver function: possible impact on the prediction of post-operative remnant liver function. HPB (Oxford). 2015;17:272-277. [PMID: 25297934 DOI: 10.1111/hpb.12348] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
254 Weiskirchen R, Wasmuth HE. The genes that underlie fatty liver disease: the harvest has begun. Hepatology. 2009;49:692-694. [PMID: 19177565 DOI: 10.1002/hep.22800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
255 Mahmoudi A, Butler AE, Jamialahmadi T, Sahebkar A. The role of exosomal miRNA in nonalcoholic fatty liver disease. J Cell Physiol 2022. [PMID: 35137416 DOI: 10.1002/jcp.30699] [Reference Citation Analysis]
256 Tada T, Kumada T, Toyoda H, Saibara T, Ono M, Kage M. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Biomarkers 2018;23:328-34. [PMID: 29308929 DOI: 10.1080/1354750X.2018.1425915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
257 Giudice EM, Grandone A, Cirillo G, Santoro N, Amato A, Brienza C, Savarese P, Marzuillo P, Perrone L. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One. 2011;6:e27933. [PMID: 22140488 DOI: 10.1159/000324178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
258 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 1009] [Article Influence: 107.8] [Reference Citation Analysis]
259 Ross AB, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol. 2013;2013:585876. [PMID: 23762052 DOI: 10.1155/2013/585876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
260 Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocrine Practice 2016;22:1-203. [DOI: 10.4158/ep161365.gl] [Cited by in Crossref: 406] [Cited by in F6Publishing: 172] [Article Influence: 67.7] [Reference Citation Analysis]
261 Brunt EM. Do you see what I see? The role of quality histopathology in scientific study. Hepatology 2008;47:771-4. [DOI: 10.1002/hep.22185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
262 Lu Y, Wang Q, Yu L, Yin X, Yang H, Xu X, Xia Y, Luo Y, Peng Y, Yu Q, Chen Z, Yu J, Lai M, Wu N, Pan XB, Zheng X. Revision of serum ALT upper limits of normal facilitates assessment of mild liver injury in obese children with non-alcoholic fatty liver disease. J Clin Lab Anal 2020;34:e23285. [PMID: 32267017 DOI: 10.1002/jcla.23285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
263 Bc B, Jaiswal RK, Gupta PK, Paudel R, Subedi RK. Carotid Intima-media Thickness in Patients with Non-alcoholic Fatty Liver Disease Attending a Tertiary Care Center: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 2021;59:454-9. [PMID: 34508436 DOI: 10.31729/jnma.5719] [Reference Citation Analysis]
264 Anderson SW, Barry B, Soto JA, Ozonoff A, O'Brien M, Jara H. Quantifying hepatic fibrosis using a biexponential model of diffusion weighted imaging in ex vivo liver specimens. Magn Reson Imaging. 2012;30:1475-1482. [PMID: 22921938 DOI: 10.1016/j.mri.2012.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
265 Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696-703. [PMID: 22331365 DOI: 10.1007/s00535-012-0534-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
266 Maher MM, Ibrahim WA, Saleh SA, Shash L, Abou Gabal H, Tarif M, Gamal M. Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egyptian Journal of Medical Human Genetics 2015;16:41-6. [DOI: 10.1016/j.ejmhg.2014.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
267 Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis. World J Gastroenterol 2014; 20(17): 4987-4993 [PMID: 24803810 DOI: 10.3748/wjg.v20.i17.4987] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
268 Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. [PMID: 22194737 DOI: 10.1155/2012/716404] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 8.9] [Reference Citation Analysis]
269 Yilmaz Y, Dolar E. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations? World J Gastroenterol 2009; 15(34): 4346-4347 [PMID: 19750583 DOI: 10.3748/wjg.15.4346] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
270 Vajro P, Lenta S, Socha P, Dhawan A, Mckiernan P, Baumann U, Durmaz O, Lacaille F, Mclin V, Nobili V. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee. Journal of Pediatric Gastroenterology & Nutrition 2012;54:700-13. [DOI: 10.1097/mpg.0b013e318252a13f] [Cited by in Crossref: 273] [Cited by in F6Publishing: 119] [Article Influence: 27.3] [Reference Citation Analysis]
271 Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010;4:623-635. [PMID: 20932147 DOI: 10.1586/egh.10.56] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
272 Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(19): 3407-3417 [PMID: 28596677 DOI: 10.3748/wjg.v23.i19.3407] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
273 Jansen C, Eischeid H, Goertzen J, Schierwagen R, Anadol E, Strassburg CP, Sauerbruch T, Odenthal M, Trebicka J. The role of miRNA -34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. PLoS One. 2014;9:e103779. [PMID: 25068403 DOI: 10.1371/journal.pone.0103779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
274 Yilmaz Y, Kurt R, Kalayci C. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments. Biomarkers in Medicine 2010;4:743-5. [DOI: 10.2217/bmm.10.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
275 Nilsson H, Blomqvist L, Douglas L, Nordell A, Janczewska I, Näslund E, Jonas E. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol 2013;86:20120653. [PMID: 23403453 DOI: 10.1259/bjr.20120653] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
276 Reeder SB, Robson PM, Yu H, Shimakawa A, Hines CD, McKenzie CA, Brittain JH. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging. 2009;29:1332-1339. [PMID: 19472390 DOI: 10.1002/jmri.21751] [Cited by in Crossref: 178] [Cited by in F6Publishing: 168] [Article Influence: 13.7] [Reference Citation Analysis]
277 Imajo K, Fujita K, Yoneda M, Shinohara Y, Suzuki K, Mawatari H, Takahashi J, Nozaki Y, Sumida Y, Kirikoshi H, Saito S, Nakamuta M, Matsuhashi N, Wada K, Nakajima A. Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study. Hepatol Res 2012;42:757-66. [PMID: 22780848 DOI: 10.1111/j.1872-034X.2012.00976.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
278 Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, Marzano A, Rizzetto M. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol. 2011;54:64-71. [PMID: 20932598 DOI: 10.1016/j.jhep.2010.06.022] [Cited by in Crossref: 158] [Cited by in F6Publishing: 152] [Article Influence: 13.2] [Reference Citation Analysis]
279 David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Correa-Giannella ML, Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Diabetes Metab Syndr Obes 2020;13:739-51. [PMID: 32231437 DOI: 10.2147/DMSO.S242282] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
280 Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010;51:500-506. [PMID: 20808246 DOI: 10.1097/mpg.0b013e3181e376be] [Cited by in Crossref: 67] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
281 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
282 Yamada K, Mizukoshi E, Seike T, Horii R, Terashima T, Iida N, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Takamura T, Harada K, Kaneko S. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2019;34:1829-35. [PMID: 30864239 DOI: 10.1111/jgh.14654] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
283 Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis. 2011;12:10-16. [PMID: 21091933 DOI: 10.1111/j.1751-2980.2010.00471.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
284 Jensen VS, Tveden-Nyborg P, Zacho-Rasmussen C, Quaade ML, Ipsen DH, Hvid H, Fledelius C, Wulff EM, Lykkesfeldt J. Variation in diagnostic NAFLD/NASH read-outs in paired liver samples from rodent models. J Pharmacol Toxicol Methods 2020;101:106651. [PMID: 31733366 DOI: 10.1016/j.vascn.2019.106651] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
285 Lalazar G, Ilan Y. Assessment of liver function in acute or chronic liver disease by the methacetin breath test: a tool for decision making in clinical hepatology. J Breath Res. 2009;3:047001. [PMID: 21386198 DOI: 10.1088/1752-7155/3/4/047001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
286 Dong Z, Luo Y, Zhang Z, Cai H, Li Y, Chan T, Wu L, Li ZP, Feng ST. MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects. PLoS One 2014;9:e111283. [PMID: 25343445 DOI: 10.1371/journal.pone.0111283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
287 Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One 2014;9:e113651. [PMID: 25470250 DOI: 10.1371/journal.pone.0113651] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 19.0] [Reference Citation Analysis]
288 Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009;50:772-780. [PMID: 19650159 DOI: 10.1002/hep.23094] [Cited by in Crossref: 136] [Cited by in F6Publishing: 132] [Article Influence: 10.5] [Reference Citation Analysis]
289 Török NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol. 2008;43:315-321. [PMID: 18592147 DOI: 10.1007/s00535-008-2181-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
290 Moschen AR, Tilg H. Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. Current Opinion in Clinical Nutrition & Metabolic Care 2008;11:620-5. [DOI: 10.1097/mco.0b013e32830b5d09] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
291 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 20.3] [Reference Citation Analysis]